Differential diagnosis and treatment of hepatic encephalopathy
- Authors: Viuchnova E.S1, Babina S.M1
-
Affiliations:
- A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 8 (2017)
- Pages: 84-88
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94897
- ID: 94897
Cite item
Abstract
In the article the main ways of differential diagnosis of hepatic encephalopathy (HE) is one of the earliest clinical manifestations of hepatocellular failure in chronic liver diseases. Diagnostic search is considered in the framework not only of the etiological factors of brain damage, but also at all stages of development of the HE, given the difficulties in establishing minimal clinical manifestations of the latent HE, with the use of psychometric tests for the detection of hidden functional disorders of brain activity and instrumental methods of diagnostics, allowing to determine the structural changes of the brain. From the perspective of the pathogenesis of HE represented a leading direction in the choice of therapy and the role of medicines L-ornithine-L-aspartate, acting on ornithology cycle, representative of which is a new domestic drug Ornilatex having pronounced hypoazotemic action.
Full Text
##article.viewOnOriginalSite##About the authors
E. S Viuchnova
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation
Email: es.vyuchnova@gmail.com
канд. мед. наук, доц. каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
S. M Babina
A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federationст. лаборант каф. пропедевтики внутренних болезней и гастроэнтерологии ФГБОУ ВО «МГМСУ им. А.И.Евдокимова» 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1
References
- Богомолов П.О., Буеверов А.О., Уварова О.В., Мациевич М.В. Латентная печеночная энцефалопатия у пациентов с минимальным фиброзом печени. Мед. совет. 2016; 10: 164-7.
- Буеверов А.О. Патогенетические основы печеночной энцефалопатии: фокус на аммиак. Клин. перспективы гастроэнтерологии, гепатологии. 2012; 6: 3-10.
- Буеверов А.О. Аммиак как нейро - и гепатотоксин: клинические аспекты. Мед. совет. 2015; 13: 80-4.
- Маев И.В., Полунина Т.Е. Печеночная энцефалопатия. Алгоритм дифференциальной диагностики и тактика ведения. РМЖ. 2010; 5: 291-6.
- Маев И.В., Вьючнова Е.С., Стасева И.В. Применение препарата L-орнитин-L-аспартата в комплексной терапии печеночной энцефалопатии у больных циррозом печени. РЖГГК. 2002; 6: 60-6.
- Маев И.В., Вьючнова Е.С., Лебедева Е.Г. и др. Оценка эффективности комплексной терапии печеночной энцефалопатии у больных циррозом печени. Клин. медицина. 2002; 5: 42-5.
- Павлов Ч.С., Дамулин И.В., Ивашкин В.Т. Печеночная энцефалопатия: патогенез, клиника, диагностика, терапия. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 1: 44-53.
- Плотникова Е.Ю. Роль L-орнитин-L-аспартата в комплексном лечении больных с гипераммониемией. Клин. перспективы гастроэнтерологии, гепатологии. 2013; 2: 41-9.
- Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии // Consilium Medicum. 2013; 15 (11): 5-9.
- Amodio P, Montagnese S, Merkel C et al. Attention: minimal hepatic encephalopathy and road accidents. Hepatology 2012; 55: 985-7.
- Blanco Vela C.I, Poo Ramirez J.L. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Ann Hepatology 2011; 10 (Suppl. 2): 55-9.
- D’Antiga L, Dacchille P, Boniver C et al. Clues for minimal hepatic encephalopathy in children with noncirrhotic portal hypertension. J Pediatr Gastroenterol Nutr 2014; 59: 689-94.
- Direkze S, Jalan R. Diagnosis and treatment of low - grade hepatic encephalopathy. Dig Dis 2015; 33: 562-9.
- Leise M.D, Poterucha J.J, Kamath P.S, Kim W.R. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014; 89 (2): 241-53.
- Ennaifer R, Cheikh M, Hefaiedh R et al. Minimal hepatic encephalopathy: a better diagnostic to improve prognostic. Presse Med 2014; 43: 127-33.
- Henderson P.K, Herrera J.L. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What? Clin Liver Dis 2015; 19 (3): 487-95.
- Sidhu S.S, Goyal O, Mishra B.P et al. Rifaximin improves psychometric performance and health - re lated quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011; 106: 307-16.
- Sharma P, Sharma B.C. Management of overt hepatic encephalopathy. J Clin Exp Hepatol 2015; 5 (Suppl. 1): 82-7.
- Sharma K, Pant S, Misra S et al. Effect of rifaximin, probiotics, and L-ornithinel - aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol 2014; 20 (4): 225-35.
- Sussman N.L. Treatment of Overt Hepatic Encephalopathy. Clin Liver Dis 2015; 19 (3): 551-63.
- Patidar K.R, Bajaj J.S. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015; 13 (12): 2048-61.
- Petersen K.U. Options in the treatment hepatic encephalopathy. Med Monatsschr Pharm 2015; 38 (5): 160-4.
- Tiberi O, Tognarelli J.M, Cook N.A et al. Diagnosing and treating hepatic encephalopathy. Br J Hosp Med 2015; 76: 646-54.
- Thrane V.R, Thrane A.S, Chang J et al. Real - timeanalysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy. Neuroscience 2013; 233: 184.
- Wang J.Y, Zhang N.P, Chi B.R et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol 2013; 9: 4984-91.
- Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015; 5 (Suppl. 1): 75-81.
Supplementary files
